Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Press releases

January 19, 2023

Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test

Read press release
January 17, 2023

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Read press release
December 5, 2022

Immunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d test

Read press release
November 30, 2022

Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia’s IMMray PanCan-d test

Read press release
November 16, 2022

Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants

Read press release
November 11, 2022

Immunovia announces the financial calendar for financial year 2023

Read press release
November 10, 2022 | REGULATORY

Immunovia Publishes Interim Report Jan-Sep 2022

Read press release
November 3, 2022

Invitation to Immunovia’s Q3 presentation

Read press release
October 20, 2022 | REGULATORY

Nomination Committee appointed for the 2023 Annual General Meeting of Immunovia AB (Publ)

Read press release
October 19, 2022

Immunovia announces executive management team changes to accelerate execution of strategic priorities

Read press release
October 17, 2022

Immunovia launches a strategic partnership with Proteomedix to leverage R&D efforts with increased focus on commercialization

Read press release
October 12, 2022

Immunovia announces positive update on physician experience program with IMMray™ PanCan-d

Read press release
1 2 3 4 5 6 27